**CDTRP Research Innovation Grant Application Form 2021**

|  |
| --- |
| Select the appropriate competition you are applying for: [ ]  CDTRP Research Innovation Grants – *Fulfilling the One-Transplant-for-Life vision***Indicate which partner competitions you would you also like to be considered for, if eligible:** [ ]  The Addison Fund / CDTRP Pediatric Research Innovation Grant (*pediatric solid organ transplant (SOT) and donation* – *BC led)* [ ]  Transplant Research Foundation of BC / CDTRP Venture Grants (*adult SOT or donation* – *led and majority of work in BC)* [ ]  CDTRP Kidney Foundation of Canada (KFOC) Research Innovation Grants[ ]  CDTRP TGLN Ontario Health Research Innovation Grant[ ]  CDTRP Université de Montréal (UdeM) Research Innovation Grant[ ]  CDTRP University Health Network (UNH) Research Innovation Grants |
| 1. Project Title      |
| 2a. Name of Principal Applicant (Underline Surname)      | 2b. Name of Co-applicant(s) (Underline Surname)      |
| 3a. Position/rank, department and/or faculty of principal applicant      | 3b. Position/rank, department and/or faculty of co-applicant(s)       |
| 4. Mailing address of principal applicant       Telephone:       E-mail:       |
| 5a. Citizenship of principal applicant       | 5b. Status in Canada (if other than citizen)      |
| 6a. Is the principal applicant an **Investigator** in the Canadian Donation and Transplantation Research Program (CDTRP)? Yes [ ]  No [ ] 6b. If not, name of CDTRP co-applicant(s):       |
| 7. Name of the payee institution (University, Hospital, Research Centre) and the contact information of the grant administration office to which the funds will be sent, should this award be granted:      |
| 8. Provide the names of 3 CDTRP members that you suggest as **potential reviewers** for your application (Please contact us at info@cdtrp.ca if you require assistance with this). We will consider these names as either potential external reviewers or members of our peer review committee; however, we cannot guarantee that these individuals will be selected:*
*
*
 |
| 9. Provide the names and justification of up to three Individuals that you request **should NOT review** your application. *
*
*
 |
| For the following sections 10 to 15, use Times New Roman or Arial font, size 11 points or larger. Use at least 0.75 inch margins around all pages. The section name and Principal Applicant name should appear in the header.10. Attach a **Summary of the Research Proposal** that highlights how the research proposal addresses the *One-Transplant-for-Life* vision – fulfilling every donor opportunity and turning transplantation into a cure. This summary will be used by the CDTRP New Initiatives Committee and funding partners to assess the relevance of the application to the scope of the competition. Applications that are not deemed eligible will be removed from the competition and will not be reviewed. Maximum length: ½ page |
| 11. Attach the **Research Proposal**. Suggested headings include 1) Statement of Objective(s), 2) Recent relevant research by applicant, 3) Brief review of literature and background information, 4) Hypothesis(es), 5) Design and Methodology, 6) Analysis of Data, 7) Anticipated Timeline, 8) Impact, Future research plans and Knowledge Translation, and 9) Budget. Maximum length: 3 pages text + 3 pages figures/tables. (page limits do not include references – these are in addition) |
| 12. A) **CDTRP Integration**: Attach a description of how this proposal will integrate within a specific Theme of the CDTRP. Maximum length: ½ page. B) We encourage you to contact the Lead or the Manager of that Theme to get advice and suggestions on how to best integrate your project ([CDTRP Research](https://cdtrp.ca/en/research/)) - a support letter from the Lead is NOT required.  |
| 13. Indicate how **sex**, as a biological variable, **gender**, as a socio-cultural factor, and **diversity** are taken into account in the research design, methods, analysis and interpretation, and/or dissemination of findings, or explain why they are not relevant / feasible within the scope of the project. For guidance and resources on how to integrate sex and gender into research, please consult the CIHR website: [https://cihr-irsc.gc.ca/e/50836.html](https://cihr-irsc.gc.ca/e/50836.html%20). Maximum length: ½ page.  |
| 14. Describe the **Patient-Family-Donor (PFD) Engagement Plan** for your project. Include a description of the key roles and responsibilities envisioned for PFD partners and how your research will benefit from PFD engagement. If PFD partnerships are not relevant / feasible within the scope of the project, explain why, and describe how the project could benefit or how they will be incorporated in future work. NOTE: PFD remuneration ($50/hr) is an eligible grant expense. See [PFD TOR](https://cdtrp.ca/en/platforms/patient-family-and-donor-researcher-partnership-platform/) for details. PFD engagement is mandatory for TRFBC-funded grants. You are encouraged to consult the [International Association for Public Participation (IAP2) levels of engagement](https://iap2canada.ca/Resources/Documents/0702-Foundations-Spectrum-MW-rev2%20%281%29.pdf), as you prepare your plan. Maximum length: ½ page.  |
| 15. Attach a **lay abstract** (max. 250 words) that can be used to explain the proposal to PFD reviewers and the general public, and that could be posted publicly if funded. This abstract should be free of jargon, technical or undefined scientific terms, and written in a manner that is easily understood by someone without prior knowledge of the subject. |
| 16. Attach a **CIHR Academic Common CV** for the **Principal Applicant**. |
| 17. OPTIONAL: Letters of Support and/or commitment from the Chair of the Department/Division indicating the level of institutional and/or university support may also be included. |

|  |
| --- |
| A. I certify that the information in this application is complete and true and I will provide supporting evidence where required. Name of principal applicant:        \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Signature of principal applicant: Date: Name of CDTRP co-applicant (if required, for non-CDTRP applicant):       \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Signature of CDTRP co-applicant: Date |
| B. Will the applicant’s project require the use of: Human subjects Yes [ ]  No [ ]  Animals Yes [ ]  No [ ]  Biohazardous materials Yes [ ]  No [ ] If yes to any of the above, the sponsoring institution shall provide the appropriate documentation granting approval to the applicant’s project for use of any of the above. **Please note that should an award be granted, funding is conditional upon receipt of all applicable documentation relating to human subjects, animals or biohazardous materials.**  |
| C. **Address for Submissions**Please send completed submissions, as a single PDF file, no later than **May 3, 2021 at 11:59pm PST** to:Dr. Julie TurgeonProgram CoordinatorCanadian Donation and Transplantation Research Program info@cdtrp.ca |

**CDTRP Research Innovation Grant Competition – 2021**

**EDI questionnaire**

The following equity, diversity and inclusion (EDI) questionnaire will allow us to collect data on important equity dimensions within our applicant pool. This page will be removed from your application before being reviewed by the peer review committee. Thank you in advance for completing this short optional questionnaire.

Please place an ‘X’ beside the most appropriate response for each question.

1. Do you identify your gender as:

[ ]  Woman

[ ]  Man

[ ]  Gender queer / non-binary

[ ]  Prefer not to disclose

1. Do you identify as a visible minority?

[ ]  Yes

[ ]  No

[ ]  Prefer not to disclose

1. Do you identify as indigenous?

[ ]  Yes

[ ]  No

[ ]  Prefer not to disclose

1. Do you identify as a person with a disability or someone who is differently-abled?

[ ]  Yes

[ ]  No

[ ]  Prefer not to disclose

1. What career stage are you currently in?

[ ]  Early career investigator (0-5 years)

[ ]  Mid career investigator (5-15 years)

[ ]  Senior investigator (15 years+)

[ ]  Prefer not to disclose